Actuate Therapeutics Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022
Period Ending	Mar '25 Mar 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022
Cash & Equivalents	3.89	8.64	2.96	20.45
Cash & Short-Term Investments	3.89	8.64	2.96	20.45
Cash Growth	88.05%	192.08%	-85.53%	-
Prepaid Expenses	0.36	0.57	0.04	0.03
Total Current Assets	4.25	9.21	3	20.48
Other Long-Term Assets	-	0.11	-	-
Total Assets	4.48	9.32	3	20.48
Accounts Payable	2.64	1.92	3.42	2.13
Accrued Expenses	6.51	6.88	3.5	2.21
Total Current Liabilities	9.15	8.8	6.92	4.34
Other Long-Term Liabilities	0.42	0.41	0.54	0.49
Total Liabilities	9.57	9.21	7.46	4.84
Common Stock	0	0	0	0
Additional Paid-In Capital	133.61	132.48	5.47	5.04
Retained Earnings	-138.7	-132.38	-105.09	-80.35
Total Common Equity	-5.09	0.1	-99.63	-75.31
Shareholders' Equity	-5.09	0.1	-4.46	15.65
Total Liabilities & Equity	4.48	9.32	3	20.48
Net Cash (Debt)	3.89	8.64	2.96	20.45
Net Cash Growth	-	192.08%	-85.53%	-
Net Cash Per Share	0.30	1.03	2.06	16.89
Filing Date Shares Outstanding	19.62	19.53	1.69	1.21
Total Common Shares Outstanding	19.53	19.53	1.69	1.21
Working Capital	-4.91	0.41	-3.93	16.14
Book Value Per Share	-0.26	0.01	-58.93	-62.21
Tangible Book Value	-5.09	0.1	-99.63	-75.31
Tangible Book Value Per Share	-0.26	0.01	-58.93	-62.21

Updated Mar 13, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q